Lineage Cell Therapeutics (LCTX) Accumulated Depreciation & Amortization (2016 - 2025)
Historic Accumulated Depreciation & Amortization for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to $2.6 million.
- Lineage Cell Therapeutics' Accumulated Depreciation & Amortization rose 4869.87% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 4869.87%. This contributed to the annual value of $1.9 million for FY2024, which is 3732.65% up from last year.
- As of Q3 2025, Lineage Cell Therapeutics' Accumulated Depreciation & Amortization stood at $2.6 million, which was up 4869.87% from $2.4 million recorded in Q2 2025.
- Lineage Cell Therapeutics' Accumulated Depreciation & Amortization's 5-year high stood at $150.0 million during Q1 2022, with a 5-year trough of $165000.0 in Q2 2021.
- In the last 5 years, Lineage Cell Therapeutics' Accumulated Depreciation & Amortization had a median value of $1.9 million in 2024 and averaged $46.1 million.
- As far as peak fluctuations go, Lineage Cell Therapeutics' Accumulated Depreciation & Amortization tumbled by 9991.79% in 2021, and later skyrocketed by 8838484.85% in 2022.
- Over the past 5 years, Lineage Cell Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $663000.0 in 2021, then fell by 12.22% to $582000.0 in 2022, then soared by 135.22% to $1.4 million in 2023, then surged by 37.33% to $1.9 million in 2024, then soared by 36.76% to $2.6 million in 2025.
- Its Accumulated Depreciation & Amortization was $2.6 million in Q3 2025, compared to $2.4 million in Q2 2025 and $2.0 million in Q1 2025.